Canopy Biosciences signs deal with Array Bridge to market kits for impurity analysis
ST. LOUIS, July 13, 2017 /PRNewswire/ — Canopy BiosciencesTM, LLC, an emerging provider of gene editing and personalized medicine technologies, announced today that it will enter the bioprocessing field by marketing kits for host cell protein detection. Array Bridge, a biotech company that developed the kits, have entered into an agreement that gives Canopy the rights to market these products.
Biologics, including monoclonal antibodies and other protein therapeutics manufactured in cells, have rapidly risen to represent a large portion of new drugs on the market, especially in oncology and inflammation. The host cell protein detection kits offered by Canopy detect the presence of protein impurities in biologics from CHO and other host cells that were used to produce the biologics.
Edward Weinstein, PhD, CEO of Canopy Biosciences said, “The host cell protein detection kits are a tremendous addition to our portfolio of technologies at Canopy. These kits help extend the breadth of our offering from gene editing and detection into bioprocessing.”
Xing Wang, PhD, CEO of Array Bridge said, “Array Bridge is very excited about this deal with Canopy—it brings together our deep knowledge of biologics development with Canopy’s strength in sales and marketing.”
To purchase a kit or learn more about them, go to Canopy’s website, www.canopybiosciences.com
About Canopy Biosciences
Canopy Biosciences was formed in 2016, partnering with leading research institutions to turn their discoveries into tangible products and make them available to the entire research community. Canopy Biosciences is headquartered in St. Louis, Missouri, and serves researchers at universities, research institutions and biotechnology and pharmaceutical companies worldwide.
Canopy Biosciences is trademarked by Canopy Biosciences, LLC.